This paper proposes a new theoretical framework for assessing the influence of risk in\ud
shaping the governance form in biopharmaceutical inter-firm relationships. In particular,\ud
we propose a multidimensional operationalization of relational and performance risk and,\ud
by following Transaction Cost Economics (TCE) and Real Options (RO) theory constructs,\ud
we hypothesize a relation between the aforementioned risk components and the choice of\ud
governance form. Specifically, following TCE reasoning, we hypothesize that a high level of\ud
relational risk leads towards more hierarchical governance forms, while, following RO\ud
theory, we hypothesize that a high level of performance risk leads toward market-oriented\ud
governance forms; finally, we hypothesize a moderating effect of each risk component on\ud
the other. We empirically test our framework through the analysis of 353 inter-firm\ud
relationships signed worldwide between pharmaceutical and biotech companies from\ud
2007 to 2010. The results show substantive support for our theoretical framework.\ud
Furthermore, we find a significant moderating effect of the performance risk on the TCE\ud
relation between relational risk and governance forms